Alergoides. Prof. Ralph Mosges

1. Prof. Dr. Paolo Falagiani (1947 – 2011)

2. 1: Liccardi G, PassalacquaG, SalzilloA, PiccoloA, FalagianiP, Russo M,
CanonicaGW, D'Amato G. Is sensitizationto furry animalsan independent allergic
phenotypein nonoccupationallyexposed individuals?J InvestigAllergol Clin
Immunol. 2011;21(2):137-41.PubMed PMID: 21462804.
2: Petrarca C, Lazzarin F, PannelliniT, Iezzi M, Braga M, MistrelloG, Falagiani
P, Di GiampaoloL, Di Gioacchino M. Monomericallergoid intragastric
administrationinduces local and systemictolerogenicresponse involving
IL-10-producingCD4(+)CD25(+) T regulatory cells in mice. Int J Immunopathol
Pharmacol. 2010 Oct-Dec;23(4):1021-31. PubMed PMID: 21244752.
3: Marogna M, MassoloA, Colombo F, Isella P, Bruno M, FalagianiP. Children
passivesmokingjeopardises the efficacyof standard anti-allergic
pharmacologicaltherapy, while sublingualimmunotherapywithstands. Allergol
Immunopathol(Madr). 2011 Mar-Apr;39(2):60-7. Epub 2011 Jan 7. PubMed PMID:
21216083.
4: Marogna M, Colombo F, Cerra C, Bruno M, MassoloA, Canonica GW, FalagianiP,
PassalacquaG. The clinicalefficacyof a sublingualmonomericallergoidat
different maintenancedoses: a randomizedcontrolledtrial. Int J Immunopathol
Pharmacol. 2010 Jul-Sep;23(3):937-45. PubMedPMID: 20943066.
5: Liccardi G, Dente B, Restani P, Senna G, FalagianiP, BallabioC, D'Amato G.
Respiratoryallergy induced by exclusivepolysensitizationto serum albuminsof
furry animals. Eur Ann Allergy Clin Immunol.2010 Jun;42(3):127-30. PubMed PMID:
20648777.
6: D'Anneo RW, Bruno ME, FalagianiP. Sublingualallergoidimmunotherapy:a new
4-day inductionphase in patientsallergic to house dust mites. Int J
ImmunopatholPharmacol. 2010 Apr-Jun;23(2):553-60. PubMed PMID: 20646350.
7: Leonardi S, Arena A, Bruno ME, Cannaò PM, D'Anneo RW, FalagianiP, Gammeri E,
MistrelloG, NicoliniA, RicciardiL, ValentiG, Longo R, La Rosa M. Olea
sublingualallergoidimmunotherapyadministeredwith two different treatment
regimens. Allergy Asthma Proc. 2010 Mar-Apr;31(2):e25-9. PubMed PMID: 20406589.
8: MinelliM, SchiavinoD, Musca F, Bruno ME, FalagianiP, MistrelloG, Riva G,
Braga M, Turi MC, Di Rienzo V, Petrarca C, SchiavoneC, Di GioacchinoM. Oral
hyposensitizationto nickel induces clinicalimprovementand a decrease in TH1
and TH2 cytokinesin patientswith systemicnickelallergy syndrome. Int J
ImmunopatholPharmacol. 2010 Jan-Mar;23(1):193-201. PubMed PMID: 20378005.
9: AgostinisF, Foglia C, Bruno ME, FalagianiP. Efficacy, safetyand
tolerabilityof sublingualmonomericallergoidin tablets given without up-dosing
to pediatric patientswith allergicrhinitis and/or asthma due to grass pollen.
Eur Ann Allergy Clin Immunol. 2009 Dec;41(6):177-80. PubMed PMID: 20128231.
10: Burastero SE, MistrelloG, Paolucci C, Breda D, Roncarolo D, Zanotta S,
FalagianiP. Clinicaland immunologicalcorrelates of pre-co-seasonal sublingual
immunotherapywith birch monomericallergoidin patientswith allergic
rhinoconjunctivitis.Int J ImmunopatholPharmacol. 2009 Apr-Jun;22(2):343-52.
PubMedPMID: 19505388.
11: Di GioacchinoM, Perrone A, Petrarca C, Di Claudio F, MistrelloG, Falagiani
P, Dadorante V, Verna N, Braga M, Ballone E, CavallucciE. Early cytokine
modulationafter the rapid inductionphase of sublingualimmunotherapywith mite
monomericallergoids.Int J ImmunopatholPharmacol. 2008 Oct-Dec;21(4):969-76.
PubMedPMID: 19144282.
12: Liccardi G, PassalacquaG, FalagianiP, Russo M, D'AmatoG. The effect of
multipleallergenson histaminerelease in vivo assessed by skin prick test.
Allergy. 2008 Nov;63(11):1559-60. PubMed PMID: 18925893.
13: Marogna M, Bruno ME, MassoloA, FalagianiP. Sublingualimmunotherapyfor
allergicrespiratory disease in elderly patients: a retrospectivestudy. Eur Ann
AllergyClin Immunol. 2008 May;40(1):22-9. PubMed PMID: 18700331.
14: D'Anneo RW, Arena A, Gammeri E, Bruno ME, FalagianiP, Riva G, Leonardi S, La
Rosa M. Parietaria sublingualallergoidimmunotherapywith a co-seasonal
treatment schedule. AllergolImmunopathol(Madr). 2008 Mar-Apr;36(2):79-84.
PubMedPMID: 18479659.
15: Burastero SE, MistrelloG, FalagianiP, PaolucciC, Breda D, Roncarolo D,
ZanottaS, MonasteroloG, Rossi RE. Effect of sublingualimmunotherapywith grass
monomericallergoidon allergen-specificT-cell proliferationand interleukin10
production. Ann Allergy Asthma Immunol. 2008 Apr;100(4):343-50. PubMed PMID:
18450120.
16: FalagianiP. Nickel hyposensitization:a literature review. Int J
ImmunopatholPharmacol. 2005 Oct-Dec;18(4 Suppl):3-5. Review. PubMed PMID:
17761097.
17: MistrelloG, Harfi H, Roncarolo D, Kwaasi A, Zanoni D, FalagianiP, Panzani
R. Date palm pollen allergoid: characterizationof its chemical-physicaland
immunologicalproperties. Int Arch Allergy Immunol. 2008;145(3):224-30.Epub 2007
Oct 3. PubMed PMID: 17914274.
18: Andri L, FalagianiP. Safety of celecoxibin patientswith cutaneous
reactionsdue to ASA-NSAIDs intolerance. Allergol Immunopathol(Madr). 2007
Jul-Aug;35(4):126-9.PubMed PMID: 17663920.
19: Giordano T, Quarta C, Bruno ME, FalagianiP, Riva G. Safety, tolerabilityand
efficacyof sublingualallergoidimmunotherapywith a 4-day shortened build-up
phase. Eur Ann Allergy Clin Immunol.2006 Nov;38(9):310-2. PubMed PMID: 17191751.
20: Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML,
Bruno ME, FalagianiP, Riva G. Clinicalefficacyand safety of preseasonal
sublingualimmunotherapywith grass pollencarbamylatedallergoidin rhinitic
patients.A double-blind,placebo-controlledstudy. Allergol Immunopathol(Madr).
2006 Sep-Oct;34(5):194-8. PubMed PMID: 17064648.
21: Marogna M, Bruno M, MassoloA, FalagianiP. Long-lastingeffectsof
sublingualimmunotherapyfor house dust mites in allergic rhinitiswith bronchial
hyperreactivity:A long-term (13-year) retrospectivestudy in real life. Int Arch
AllergyImmunol. 2007;142(1):70-8. Epub 2006 Oct 2. PubMed PMID: 17016060.
22: Baruffini A, Pisati G, RusselloM, FalagianiP. [Occupationalallergic
IgE-mediateddiseasefrom Boletus edulis: case report]. Med Lav. 2005
Nov-Dec;96(6):507-12. Italian.Erratum in: Med Lav. 2006 Jan-Feb;97(1):87. PubMed
PMID: 16983976.
23: PassalacquaG, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I,
MajaniG, FalagianiP, Bruno M, Canonica GW. Randomizeddouble-blindcontrolled
study with sublingualcarbamylatedallergoidimmunotherapyin mild rhinitisdue
to mites. Allergy. 2006 Jul;61(7):849-54. PubMed PMID: 16792583.
24: Cosmi L, SantarlasciV, Angeli R, LiottaF, Maggi L, Frosali F, Rossi O,
FalagianiP, Riva G, Romagnani S, AnnunziatoF, Maggi E. Sublingualimmunotherapy
with Dermatophagoidesmonomericallergoiddown-regulates allergen-specific
immunoglobulinE and increases both interferon-gamma-and
interleukin-10-production.Clin Exp Allergy. 2006 Mar;36(3):261-72. PubMed PMID:
16499636.
55: Liccardi G, Russo M, MistrelloG, FalagianiP, D'AmatoM, D'Amato G.
Sensitizationto pistachiois common in Parietaria allergy. Allergy. 1999
Jun;54(6):643-5. PubMed PMID: 10435484.
25: Bagnasco M, AltrinettiV, Pesce G, Caputo M, MistrelloG, FalagianiP,
CanonicaGW, PassalacquaG. Pharmacokineticsof Der p 2 allergen and derived
monomericallergoidin allergic volunteers. Int Arch Allergy Immunol. 2005
Nov;138(3):197-202.Epub 2005 Oct 3. PubMed PMID: 16205097.
26: PassalacquaG, AltrinettiV, Mariani G, FalagianiP, MistrelloG, Brizzolara
R, Canonica GW, Bagnasco M. Pharmacokineticsof radiolabelledPar j 1
administeredintranasallyto allergicand healthy subjects. Clin Exp Allergy.
2005 Jul;35(7):880-3. PubMed PMID: 16008673.
27: Asero R, MistrelloG, Roncarolo D, Amato S, FalagianiP. Why do lipid
transfer protein-hypersensitivepatientstoleratebean (and other legumes)? Int
Arch Allergy Immunol.2005 Jul;137(3):236-40. Epub 2005 Jun 13. PubMed PMID:
15956792.
28: Asero R, MistrelloG, Roncarolo D, Amato S, FalagianiP. Detectionof novel
latexallergens associatedwith clinicallyrelevant allergy to plant-derived
foods. J Allergy Clin Immunol. 2005 Jun;115(6):1312-4. PubMed PMID: 15940153.
29: AgostinisF, TellariniL, Canonica GW, FalagianiP, PassalacquaG. Safety of
sublingualimmunotherapywith a monomericallergoidin very young children.
Allergy. 2005 Jan;60(1):133. PubMed PMID: 15575951.
30: Marogna M, FalagianiP, Bruno M, Massolo A, Riva G. The allergic march in
pollinosis: natural history and therapeuticimplications.Int Arch Allergy
Immunol. 2004 Dec;135(4):336-42. Epub 2004 Nov 24. PubMed PMID: 15564776.
31: Lombardi C, Gani F, Landi M, FalagianiP, Bruno M, Canonica GW, Passalacqua
G. Quantitativeassessment of the adherence to sublingualimmunotherapy.J
AllergyClin Immunol. 2004 Jun;113(6):1219-20. PubMed PMID: 15214362.
32: Hilger C, Thill L, Grigioni F, Lehners C, FalagianiP, Ferrara A, Romano C,
StevensW, Hentges F. IgE antibodiesof fish allergic patientscross-react with
frog parvalbumin.Allergy. 2004 Jun;59(6):653-60. PubMed PMID: 15147451.
33: Andri L, FalagianiP. Symptomaticrelief after grass nasal immunotherapy:
lastingefficacyafter 4-5 years. J InvestigAllergol Clin Immunol.
2003;13(4):228-31.PubMed PMID: 14989110.
34: Asero R, MistrelloG, Roncarolo D, Amato S, FalagianiP. Analysisof the heat
stabilityof lipid transfer protein from apple. J Allergy Clin Immunol.2003
Nov;112(5):1009-11.PubMed PMID: 14610497.
35: Bagnasco M, Morbelli S, AltrinettiV, FalagianiP, MarianiG, PassalacquaG.
Allergenbiodistributionin humans. Chem ImmunolAllergy. 2003;82:33-43. Review.
PubMedPMID: 12947990.
36: Ballero M, Ariu A, FalagianiP. Allergy to Ailanthusaltissima(tree of
heaven) pollen. Allergy. 2003 Jun;58(6):532-3. PubMed PMID: 12757458.
37: MistrelloG, Roncarolo D, Zanoni D, Zanotta S, Amato S, FalagianiP, Ariano
R. Allergenicrelevance of Cupressus arizonicapollen extract and biological
characterizationof the allergoid. Int Arch Allergy Immunol. 2002
Dec;129(4):296-304.PubMed PMID: 12483034.
38: Di Rienzo V, FalagianiP, Frati F, Sensi L, MarcucciF. Unusual IgE-mediated
allergyto fish bait. Allergy. 2002 Sep;57(9):869-70. PubMed PMID: 12169198.
39: Meglio P, Plantamura M, Arabito E, FalagianiP, Torre A, Rossi P. Does SIT to
Der p protect from snail sensitization?Allergy. 2002 Sep;57(9):868-9. PubMed
PMID: 12169197.
40: Tripodi S, FalagianiP, PerinelliT, Dell'OmoF, CristaldiA. Allergy to
fishingbait. Allergy. 2002 Jul;57(7):653. PubMed PMID: 12100315.
41: PocobelliD, Del Bono A, Venuti L, FalagianiP, Venuti A. Nasal immunotherapy
at constant dosage: a double-blind, placebo-controlledstudy in grass-allergic
rhinoconjunctivitis.J InvestigAllergol Clin Immunol.2001;11(2):79-88. PubMed
PMID: 11642577.
42: Lombardi C, Gargioni S, Melchiorre A, Tiri A, FalagianiP, Canonica GW,
PassalacquaG. Safety of sublingualimmunotherapywith monomeric allergoidin
adults: multicenterpost-marketingsurveillancestudy. Allergy. 2001
Oct;56(10):989-92.PubMed PMID: 11576079.
43: Asero R, MistrelloG, Roncarolo D, Casarini M, FalagianiP. Allergy to
nonspecificlipidtransfer proteins in Rosaceae: a comparativestudy of different
in vivo diagnosticmethods. Ann Allergy Asthma Immunol.2001 Jul;87(1):68-71.
PubMedPMID: 11476467.
44: PassalacquaG, Villa G, AltrinettiV, FalagianiP, Canonica GW, MarianiG,
BagnascoM. Sublingualswallow or spit? Allergy. 2001 Jun;56(6):578. PubMed PMID:
11421908.
45: Arena A, CislaghiC, FalagianiP. Anaphylacticreactionto the ingestionof
raw onion. A case report. Allergol Immunopathol(Madr). 2000 Sep-Oct;28(5):287-9.
PubMedPMID: 11270091.
46: Bagnasco M, Passalacqua G, Villa G, Augeri C, FlamigniG, Borini E, Falagiani
P, MistrelloG, Canonica GW, Mariani G. Pharmacokineticsof an allergen and a
monomericallergoidfor oromucosal immunotherapyin allergicvolunteers. Clin Exp
Allergy. 2001 Jan;31(1):54-60. PubMed PMID: 11167951.
47: Angiola Crivellaro M, Senna G, Riva G, CislaghiC, FalagianiP, Walter
CanonicaG, PassalacquaG. Pollen mixturesused as health food may be a harmful
source of allergens. J InvestigAllergol Clin Immunol.2000 Sep-Oct;10(5):310-1.
PubMedPMID: 11108445.
48: Senna GE, Andri G, Dama AR, FalagianiP, Andri L. Local nasal immunotherapy:
efficacyand tolerabilityof two different administrationschedulesin grass
pollenrhinitis. AllergolImmunopathol(Madr). 2000 Jul-Aug;28(4):238-42. PubMed
PMID: 11022271.
49: Corsico R, FalagianiP, Ariano R, Berra D, Biale C, BonifaziF, Campi P,
FelizianiV, FrenguelliG, GalimbertiM, Gallesio MT, Liccardi G, Loreti A,
Marcer G, Marcucci F, Meriggi A, MinelliM, Nardelli R, Nardi G, Negrini CA, Papa
G, Piu G, Pozzan M, D'AmbrosioFP, Riva G. An epidemiologicalsurvey on the
allergologicalimportanceof some emerging pollens in Italy. J InvestigAllergol
Clin Immunol.2000 May-Jun;10(3):155-61. PubMedPMID: 10923590.
50: Romano C, Ferrara A, FalagianiP. A case of allergy to globe artichoke and
other clinicalcases of rare food allergy. J InvestigAllergol Clin Immunol. 2000
Mar-Apr;10(2):102-4. PubMed PMID: 10879999.
51: Romano C, Ferrara AM, CislaghiC, FalagianiP. Food allergy to frog. Allergy.
2000 Jun;55(6):584-5. PubMed PMID: 10858996.
52: FalagianiP. Intranasalimmunotherapy. Allergy. 1999;54 Suppl 58:53-5.
Review. PubMed PMID: 10735653.
53: Asero R, MistrelloG, Roncarolo D, Casarini M, FalagianiP. True
monosensitivityto a tropical sole. Allergy. 1999 Nov;54(11):1228-9. PubMed PMID:
10604565.

3. 54: Crimi E, VoltoliniS, Minale P, FalagianiP. Value of immunoglobulinE
densityin predictingnasal and bronchial response to inhaledallergens in
rhiniticand asthmaticsubjectswith multiplesensitizations.Clin Exp Allergy.
1999 Dec;29(12):1663-70. PubMed PMID: 10594543.
55: Liccardi G, Russo M, MistrelloG, FalagianiP, D'AmatoM, D'Amato G.
Sensitizationto pistachiois common in Parietaria allergy. Allergy. 1999
Jun;54(6):643-5. PubMed PMID: 10435484.
56: Asero R, MistrelloG, Roncarolo D, AntoniottiPL, FalagianiP. A case of
sesameseed-induced anaphylaxis.Allergy. 1999 May;54(5):526-7. PubMed PMID:
10380788.
57: Asero R, MistrelloG, Roncarolo D, AntoniottiP, CislaghiC, FalagianiP. A
new apple extract. Allergy. 1999 Jan;54(1):87-8. PubMed PMID: 10195370.
58: Roncarolo D, MinaleP, MistrelloG, VoltoliniS, FalagianiP. Food allergy to
Boletusedulis. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):850-1. PubMed PMID:
9648715.
59: PassalacquaG, Bagnasco M, Mariani G, FalagianiP, Canonica GW. Local
immunotherapy: pharmacokineticsand efficacy. Allergy. 1998 May;53(5):477-84.
Review. PubMed PMID: 9636806.
60: MistrelloG, Gentili M, Roncarolo D, AntoniottiP, Ottoboni F, FalagianiP.
Dot immunobindingassay for detectionof mite antigens in house-dust samples. J
Med Entomol. 1998 Mar;35(2):143-7. PubMed PMID: 9538574.
61: Asero R, MistrelloG, Roncarolo D, AntoniottiPL, FalagianiP. A case of
garlic allergy. J Allergy Clin Immunol.1998 Mar;101(3):427-8. PubMed PMID:
9525465.
62: Pisati G, BaruffiniA, Bernabeo F, FalagianiP. Environmentaland clinical
study of latex allergy in a textilefactory. J Allergy Clin Immunol. 1998
Mar;101(3):327-9. PubMed PMID: 9525447.
63: Coppola V, Veronesi A, IndraccoloS, Calderazzo F, Mion M, MinuzzoS,
EspositoG, Mauro D, SilvestriB, Gallo P, FalagianiP, Amadori A, Chieco-Bianchi
L. Lymphoproliferativedisease in human peripheral blood mononuclear
cell-injectedSCID mice. IV. Differentialactivationof human Th1 and Th2
lymphocytesand influenceof the atopic status on lymphomadevelopment.J
Immunol. 1998 Mar 1;160(5):2514-22. PubMed PMID: 9498797.
64: PassalacquaG, Albano M, Pronzato C, Riccio AM, ScordamagliaA, FalagianiP,
CanonicaGW. Long-term follow-up of nasal immunotherapyto Parietaria: clinical
and local immunologicaleffects. Clin Exp Allergy. 1997 Aug;27(8):904-8. PubMed
PMID: 9291287.
65: Bagnasco M, Mariani G, PassalacquaG, Motta C, Bartolomei M, FalagianiP,
MistrelloG, Canonica GW. Absorption and distributionkineticsof the major
Parietariajudaica allergen (Par j 1) administeredby noninjectableroutes in
healthyhuman beings. J Allergy Clin Immunol. 1997 Jul;100(1):122-9. PubMed PMID:
9257796.
66: Asero R, MistrelloG, Roncarolo D, AntoniottiP, FalagianiP.
Exercise-inducedegg anaphylaxis. Allergy. 1997 Jun;52(6):687-9. PubMed PMID:
9226076.
67: Asero R, MistrelloG, FalagianiP. Oral allergy syndrome from pork. Allergy.
1997 Jun;52(6):684-6. PubMed PMID: 9226073.
68: Zardi O, Zardi EM, FalagianiP, Zardi DM, Zardi MC, Barduagni F, Barduagni O.
[Subcutaneoushuman dirofilariasis]. Pathologica.1997 Feb;89(1):31-5. Review.
Italian.PubMed PMID: 9312730.
69: Canonica GW, Passalacqua G, Mariani G, Motta C, BartolomeiM, MistrelloG,
FalagianiP, Bagnasco M. Oral routes for immunotherapy:clinicalefficacyand
kineticsof the allergen. Arb Paul Ehrlich Inst Bundesamt Sera ImpfstoffeFrankf
A M. 1997;(91):56-64; discussion64-7. Review. PubMed PMID: 9383892.
70: FalagianiP, MistrelloG. Pharmacokineticsof allergens after local
administration. Allergy. 1997;52(33 Suppl):17-21. Review. PubMed PMID: 9188942.
71: Liccardi G, MistrelloG, Noschese P, FalagianiP, D'AmatoM, D'Amato G. Oral
allergysyndrome (OAS) in pollinosispatientsafter eating pistachionuts: two
cases with two different patterns of onset. Allergy. 1996 Dec;51(12):919-22.
PubMedPMID: 9020420.
72: D'Amato G, Russo M, Liccardi G, Saggese M, GentiliM, MistrelloG, D'Amato M,
FalagianiP. Comparison between outdoor and indoor airborne allergenicactivity.
Ann Allergy Asthma Immunol. 1996 Aug;77(2):147-52. PubMed PMID: 8760781.
73: MistrelloG, Brenna O, Roncarolo D, Zanoni D, GentiliM, FalagianiP.
Monomericchemicallymodifiedallergens: immunologicand physicochemical
characterization. Allergy. 1996 Jan;51(1):8-15. PubMed PMID: 8721522.
74: Andri L, Senna G, Betteli C, Givanni S, Andri G, DimitriG, FalagianiP,
MezzelaniP. Local nasal immunotherapywith extract in powder form is effective
and safe in grass pollen rhinitis: a double-blindstudy. J Allergy Clin Immunol.
1996 Jan;97(1 Pt 1):34-41. PubMed PMID: 8568135.
75: Andri L, Senna G, Andri G, Dama A, Givanni S, BetteliC, DimitriG, Falagiani
P, MezzelaniP. Local nasal immunotherapyfor birch allergicrhinitis with
extract in powder form. Clin Exp Allergy. 1995 Nov;25(11):1092-9. PubMed PMID:
8581842.
76: MistrelloG, Gentili M, FalagianiP, Roncarolo D, Riva G, TinelliM. Dot
immunobindingassay as a new diagnostictest for human hydatiddisease. Immunol
Lett. 1995 Jul-Aug;47(1-2):79-85. PubMed PMID: 8537105.
77: Romano C, Sulotto F, PiolattoG, Ciacco C, Capellaro E, FalagianiP,
ConstableDW, Verga A, ScansettiG. Factors related to the development of
sensitizationto green coffee and castor bean allergens among coffee workers.
Clin Exp Allergy. 1995 Jul;25(7):643-50. PubMed PMID: 8521183.
78: Panzani RC, FalagianiP, Riva G, Delord Y, Mercier P. Screening for atopy in
a coffee-processingfactory. Int Arch Allergy Immunol. 1995
May-Jun;107(1-3):443-4. PubMed PMID: 7613207.
79: Ariano R, Panzani RC, ChiapellaM, Augeri G, FalagianiP. Local intranasal
immunotherapywith allergen in powder in atopic patientssensitiveto Parietaria
officinalispollen. J InvestigAllergol Clin Immunol.1995 May-Jun;5(3):126-32.
PubMedPMID: 7582157.
80: Panzani RC, FalagianiP, Riva G, Delord Y, Mercier P. Screening for atopy in
a coffee processing factory. Allergol Immunopathol(Madr). 1995
Jan-Feb;23(1):29-34. PubMedPMID: 7631592.
81: FalagianiP, MistrelloG, Rapisarda G, Festa A, CislaghiC, Zanoni D.
Evaluationof allergenicpotency by REAST inhibition. A new tool for the
standardizationof allergenicextracts. J ImmunolMethods. 1994 Aug
1;173(2):181-90. PubMed PMID: 8046253.
82: D'Amato G, GentiliM, Russo M, MistrelloG, Saggese M, Liccardi G, Falagiani
P. Detectionof Parietaria judaica airborne allergenicactivity: comparison
betweenimmunochemicaland morphologicalmethodsincludingclinicalevaluation.
Clin Exp Allergy. 1994 Jun;24(6):566-74. PubMed PMID: 7922776.
83: MistrelloG, Roncarolo D, GentiliM, Zanoni D, FalagianiP. Modifiedpar j I
allergenfrom P judaicapollen and its rate of absorptionin rats. ImmunolLett.
1994 Apr;40(1):31-6. Erratum in: ImmunolLett 1994 Jul;41(2-3):291. PubMed PMID:
7927511.
84: Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello
G, FalagianiP, Geraci D. cDNA cloning, expression and primary structure of Par
jI, a major allergen of Parietaria judaica pollen. FEBS Lett. 1994 Mar
21;341(2-3):182-6. PubMed PMID: 8137937.
85: Panzani RC, Mercier P, Delord Y, Riva G, FalagianiP, Reviron D, Auquier P.
Prevalenceof patent and latent atopy among a general normal adult populationin
the south east of France by RAST investigationand correlation with circulating
totalIgE levels. Allergol Immunopathol(Madr). 1993 Nov-Dec;21(6):211-9. PubMed
PMID: 8160568.
86: Caneva E, Di Gennaro P, Farina F, Orlandi M, Rindone B, FalagianiP.
Synthesisand characterizationof a penicillin-poly(L-lysine)which recognizes
humanIgE anti-penicillinantibodies. BioconjugChem. 1993 Sep-Oct;4(5):309-13.
PubMedPMID: 8274512.
87: Andri L, Senna G, Betteli C, Givanni S, Andri G, FalagianiP. Local nasal
immunotherapyfor Dermatophagoides-inducedrhinitis: efficacyof a powder
extract. J Allergy Clin Immunol. 1993 May;91(5):987-96. PubMed PMID: 8491949.
88: Ariano R, Panzani RC, FalagianiP, ChiapellaM, Augeri G. Respiratory allergy
to the pollen of Mercurialisannua (Euphorbiaceae). Ann Allergy. 1993
Mar;70(3):249-54. PubMed PMID: 8452320.
89: Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, FalagianiP.
Rheumatoidarthritiswith monoclonalIgE rheumatoidfactor. J Rheumatol. 1993
Mar;20(3):489-94. PubMed PMID: 8386767.
90: Panzani RC, FalagianiP, Riva G, Mercier P, Delord. Screening for IgE
mediatedallergyamong people working in the Marseillesharbour. Allergol
Immunopathol(Madr). 1993 Jan-Feb;21(1):25-9. PubMed PMID: 8328353.
91: Andri L, Senna GE, BetteliC, Givanni S, Andri G, FalagianiP, Lugo G. Local
nasal immunotherapyin allergicrhinitis to Parietaria. A double-blindcontrolled
study. Allergy. 1992 Aug;47(4 Pt 1):318-23. PubMed PMID: 1443452.
92: BolzacchiniE, Di Gennaro P, Di Gregorio G, Rindone B, FalagianiP, Mistrello
G, Sondergaard I. Purificationof Phleum pratense pollen extract by
immunoaffinitychromatographyand high-performanceion-exchangechromatography.J
Chromatogr. 1991 Jul 12;548(1-2):229-34. PubMed PMID: 1939423.
93: Del Prete GF, De Carli M, MastromauroC, BiagiottiR, MacchiaD, FalagianiP,
RicciM, RomagnaniS. Purified protein derivativeof Mycobacteriumtuberculosis
and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T
cellswith stable and opposite (type 1 T helper or type 2 T helper) profile of
cytokineproduction. J Clin Invest. 1991 Jul;88(1):346-50. PubMed PMID: 1829097;
PubMedCentral PMCID: PMC296040.
94: BolzacchiniE, Di Gennaro P, Di Gregorio G, Rindone B, FalagianiP, Mistrello
G, Sondergaard I. Allergenicfragments in Parietaria judaica pollen extract. J
Chromatogr. 1991 Apr 12;542(2):337-44. PubMed PMID: 1715346.
95: Moscato G, DellabiancaA, FalagianiP, MistrelloG, Rossi G, RampullaC.
Inhaledfurosemideprevents both the bronchoconstrictionand the increase in
neutrophilchemotacticactivityinducedby ultrasonic"fog" of distilledwater in
asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561-6. PubMed PMID: 2001067.
96: MistrelloG, Rapisarda G, FalagianiP. Detectionof IgE-bindingactivityin
serum after intranasaltreatment of normal rabbits with P. judaica extract.
Allergy. 1991 Jan;46(1):52-8. PubMed PMID: 2018209.
97: FalagianiP. Thimerosalin standard antigenicextracts. Contact Dermatitis.
1989 Nov;21(5):354. PubMed PMID: 2620521.
98: Cocchiara R, Locorotondo G, Parlato A, Guarnotta G, Ronchi S, AlbeggianiG,
Amoroso S, FalagianiP, Geraci D. Purificationof Parj I, a major allergen from
Parietaria, judaicapollen. Int Arch Allergy Appl Immunol. 1989;90(1):84-90.
PubMedPMID: 2478488.
99: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, FalagianiP,
Riva G, BolzacchiniE. Micropreparative-scaleenrichment of some allergenic
componentsof Parietaria pollen extract. J Chromatogr. 1988 Jul 27;446:179-85.
PubMedPMID: 3209654.
100: Genchi C, FalagianiP, Riva G, TinelliM, Brunello F, Boero M, AlmavivaM.
IgE and IgG antibodiesin Toxocara canis infection.A clinicalevaluation.Ann
Allergy. 1988 Jul;61(1):43-6. PubMed PMID: 3389570.
101: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, FalagianiP,
Riva G, BolzacchiniE. Analysisof allergeniccomponentsof a Parietaria judaica
pollenextract by chromatographicmethodsfor the evaluationof purification
procedures. J Chromatogr. 1988 Jul 1;444:209-18. PubMed PMID: 3204131.
102: BolzacchiniE, Di Gregorio G, Nali M, Rindone B, Tollari S, FalagianiP,
Riva G, Crespi G. Purificationand molecularweight studies on the componentsof
a Parietaria pollen extract. Allergy. 1988 Jan;43(1):53-9. PubMed PMID: 3344935.
103: Amoroso S, Cocchiara R, Locorotondo G, Parlato A, LampiasiN, AlbeggianiG,
FalagianiP, Geraci D. Antigensof Euparipha pisana (snail). I. Identificationof
allergensby means of in vivo and in vitro analysis. Int Arch Allergy Appl
Immunol. 1988;85(1):69-75. PubMedPMID: 2448245.
104: TinelliM, FalagianiP, Riva G, Genchi C. RAST and ELISA in three
autochthonousparasiticinfectionsin Italy: toxocariasis, hydatidosisand
fascioliasis. Boll Ist Sieroter Milan. 1987;66(1):38-45. PubMed PMID: 3620121.
105: Sgambato F, PediciniA, De Rienzo D, FalagianiP. [Inhalationallergy to fly
larva. A clinicalcase]. Boll Ist Sieroter Milan. 1987;66(5):411-5. Italian.
PubMedPMID: 3449104.
106: Boner AL, Vallone G, Bennati D, FalagianiP, Gaburro D. Simplifiedspinhaler
methodfor antigen-specificbronchoprovocationin children with bronchial asthma.
I. Ann Allergy. 1986 Nov;57(5):363-6. PubMed PMID: 3777536.
107: Brunello F, FalagianiP, Genchi C. Enzyme immunoassay(ELISA) for the
detectionof specificIgG antibodiesto Toxocara canis ES antigens. Boll Ist
Sieroter Milan. 1986;65(1):54-60. Erratum in: Boll Ist Sieroter Milan
1986;65(5):following445. PubMed PMID: 3718679.
08: Genchi C, TinelliM, Brunello F, FalagianiP. Serodiagnosisof ocular
toxocariasis:a comparisonof specificIgE and IgG. Trans R Soc Trop Med Hyg.
1986;80(6):993-4. PubMed PMID: 3603652.
109: FalagianiP, Cavallone E, Nali M, Rindone B, Tollari S, Crespi G. Aqueous
size-exclusionanalysisof Parietaria pollen extracts. J Chromatogr. 1985 Jun
28;328:425-31.PubMed PMID: 4030974.

4. An impressively productive scientific mind

5. Il dosaggio radio-immunologico delle reagine
del secreto nasale.
• Boll Soc Ital Biol Sper.
• 1977 Feb 15 ; 53(3):188-92.
• Crifò S, Falagiani P, Filiaci F, Andriani G.

7. The author of numerous books

8. Concept of the
monomeric allergoid

11. The novel view
on specific
immunotherapy

12. The Idea:
To combine the advantages of
allergoids together with the
sublingual route into a better
effective and more safe
Immunotherapy
The first specific sublingual immuntherapy
with allergoids available as tablets & drops

13. Maintained
conformation
for T-cell-binding
Chemical modification of
residual peripheral
aminoacid-sequences
Reduced IgE binding affinity

14. Allergens
The unmodified molecule is destroyed
by the attack of enzymes.
Sublingual Allergoides
the modified molecule resists to
enzymatic coupling and remains intact.
The first specific sublingual immuntherapy
with allergoids available as tablets & drops

15. The novel approach
Allergen extracts are chemically transformed, the
Carbamylation, to replace parts of the protein
components, and to maintain the molecular dimensions.
Monomerization
(Monoid)
The first specific sublingual immuntherapy
with allergoids available as tablets & drops

16. 1-Reduction of the Allergenicity
2-Maintenance of the Antigenicity
3-Maintenance of the Molecular Dimension
4-Resistance against Enzymatic Digestion
5-Absence of Toxicity
Characterization of the sublingual
carbamylated allergoid (Monoid)

17. Concept Overview
Allergen Type Antigenity
Allergenicit
y
Proteine
Structure
Enzymatic
Protection
Monoid Maintained
Reduced
(targeted)
Modified,
complex
(„Segments
cut“)
Shown
Native Allergen Maintained Maintained Nativ, complex Not shown
Allergoid
Reduced
(Not
targeted)
Reduced
(targeted)
Polymerized Not shown

18. Allergoid
SLIT
oral
mucosa
gastrointestinal
mucosa
APC Lymphozytes
Lymphatic
system
systemic
circulation
capillaries
clinical
results
Route of action in the oromucosal and
gastrointestinal system

19. Pharmacokinetics
& Immunology

20. To study the pharmacokinetics
in allergic volunteers
of allergoid sublingual immunotherapy
in oromucosal tablets
Objective
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G..
Clinical Immunology Service, DIMI, Genoa, Italy

21. Radiolabelled monomeric allergoid and native allergen, administered to 8
allergic pts and 1 non atopic, were detected by scintigraphic acquisitions.
Plasma radioactivity was measured at different intervals.
Methods
The increased resistance to gastrointestinal enzymatic degradation can explain
the high absorption of the monomeric allergoid and its appearance in the
bloodstream.
The local persistence of the monomeric allergoid and allergen may involve the
mucosal immunity in the mechanism of action of antiallergic vaccination.
Results
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G..
Clinical Immunology Service, DIMI, Genoa, Italy

22. PlasmaticRadioactivity
Hrs after application
Sublingual allergoids
in form of tablets
Native Allergens
in form of tablets
Native Allergens
in liquid solution
I
2
I
5
I
1
I
15
1 -
3 -
5 -
ALLERGO Kinetics
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al.
Clinical Immunology Service, DIMI, Genoa, Italy

23.  Systemic absorption
 Mucosal immunity involvement
Conclusions
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al.
Clinical Immunology Service, DIMI, Genoa, Italy

24. Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,
Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Objective
Methods
To show the immunological effects of a sublingual carbamylated allergoid.
25 pts: with rhinitis / asthma to Der p1, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. 1,5 years of treatment.
Treated group: 12 Lais Der p1
Placebo group: 13

25. the sublingual allergoid increases the
production of the cytokines IL-10 & IFN-
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results

26. the sublingual allergoid reduces the
production of spezific IgE
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results

27. Clear immunological effects have been shown under
treatment with a sublingual carbamylated allergoid.
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al.
Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Conclusion

28. DBPC Trials Results

29. Sublingual Allergoids
efficacy (subjective data)
• Reduction of symptoms of asthma
• Reduction of symptoms of rhinoconjunctivitis
• Reduction of symptomatic medication
Results from recent
(DBPC) Trials

30. Sublingual allergoids
efficacy (objective data)
Efficacy was assessed using objective measurements:
• increase of the provocative dose
specifically in nasal provocation test
unspecifically with Metacholine
Results from recent
(DBPC) Trials

31. Sublingual allergoids
Safety
The safety of treatment is supported by
numerous published clinical studies.
The sublingual allergoid, the Monoid, has
demonstrated its safety also in patients with
Oral Allergy Syndrome (OAS).
Results from recent
(DBPC) Trials

32. Sublingual allergoids
Tolerability
Tolerability is supported by data from numerous
clinical trials
Results from recent
(DBPC) Trials

33. Sublingual allergoids
Compliance
Compliance, adherence with the treatment is excellent as
demonstrated by:
•Pill count in clinical trials.
•Repetitive prescription in real life studies.
Results from recent
(DBPC) Trials

34. Results from recent
(DBPC) Trials

35. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Material & methods
48 pts: 8 yrs mean age, Rhinoconjunctivitis/Asthma
to Grass. DBPC study. Positive anamnesis,
SPT and RAST. ECP, symptoms, drug score
and Compliance recorded.
Protocol: preseasonal scheduling.
IT treated: 24 Lais Grass.
Drug treated: 20 (4 drop out).

36. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores in pollen season
Good compliance.
Results
No differences in placebo group.

37. Reduction of total symptom score
during treatment with sublingual allergoids  vs Placebo 
During the grass pollen season.
score
5 -
I
Symptome
NASAL
N S
10 -
15 -
I
Symptome
OCULAR
N S
p<0.05
I
Symptome
BRONCHIAL
I
Symptome
TOTAL
p<0.05
I
Rescue medication
N S
Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy

38. Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni
Paediatric Departments of Parma, Perugia and Sassuolo, Italy
The preseasonal course with Lais Grass
as Allergoid SLIT:
is effective in the reduction of respiratory
symptoms of children,
in particular asthma, within 3,5 months
Conclusions

39. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
33 pts: with rhinitis / asthma to Phl p5, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo
Treated group: 17 Lais 3-Gras Mix
Placebo group: 16
Material & Methods

40. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Design

41. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G.
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Results
Improvement of the nasal provocation test
Reduction of rhinoconjunctivitis symptoms

42. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Results
Reduction of steroid consumption

43. Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal
Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
SLIT in gras allergic patients is effective and reduces
single symptoms between 40 - 60 %
and
co-medication (steroids) vs. placebo up to 80%
(at pollen peak)
Conclusions

44. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
30 pts: with rhinitis / asthma to Par j, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. Dec.92 to Jul.95.
Treated group: 15 Lais Par j (1 drop out).
Placebo group: 15
Material & methods

45. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Statistically significant differences in the
Allergoid SLIT treated group:
Reduced symptoms score (in particular during pollen season).
Reduced medication score.
Increased threshold dose with Allerkin Test.
Increased threshold dose with Methacholine Lofarma.
Results
No differences in placebo group.

46. Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri*
*Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Hyposensitization with Parietaria pollen as
Allergoid SLIT
is a safe and efficaceous vaccine
which may be used in children and adults.
Conclusions

47. The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy
20 pts: per. rhinoconjunctivitis to Der, positive to
anamnesis, prick, RAST and SCPT.
Inflammatory-cells and ICAM-1 and
serum inflam. markers (ECP) recorded.
Protocol: double blind vs placebo. Apr.94 to Mar.96.
Treated group: 10 Lais Der p&f.
Placebo group: 10 (1 drop out).
Material & methods

48. Statistically significant differences in
The monomeric Allergoid SLIT group:
Reduced symptom & medication scores.
Reduced inflammatory infiltration and ICAM-1 expression.
Reduced MPI, the Minimal Persistent Inflammation.
Results
No differences in placebo group.
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy

49. Reduction of inflammation
After 24 months of treatment with sublingual allergoids vs Placebo 
Demonstrated by conjunctival provocation test
ICAM1
I
24 Months
I
T 0
1 -
3 -
N S
p<0.001
EOSINOFILE
I
24 Months
I
T 0
1 -
3 -
N S
0.001
NEUTROFILE
I
24 Months
I
T 0
5 -
10 -
N S
0.001
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy

50. Hyposensitization with Dermatophagoides
as Allergoid SLIT:
l reduces the allergic inflammation
l is safe and clinically effective.
Conclusions
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al.
Clinical Immunology Service, DIMI, Genoa, Italy

52. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
Material & methods
39 pts: Rhinoconjunctivitis / Asthma (50%) to Par.
Positive anamnesis, SPT, PFT and SNPT.
Serum inflam. markers (ECP) recorded.
Symptoms & Drug Score, QoL.
Protocol: clustered treatment according to Data Sheet.
IT treated: 27 Lais Par.
Drug treated: 12 (3 drop out).

53. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores.
Improved Quality of Life, assessed by questionnaire.
Good compliance, over 80% .
Results
No differences in placebo group.

54. Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri
Napoli, Medical Dept Lofarma S.p.A.Italy
The Clustered Treatment with Parietaria as
Allergoid SLIT:
l is a suitable treatment when it is too
late to start a conventional scheduling
l is well tolerated and safe.
Conclusions

55. To study the safety of ultra
rush SLIT with four commercial
products in allergic patients.
Objective
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy

56. Ninety-one allergic patients with rhino-conjunctivitis
and/or asthma.
Prospective observational, 36 months follow-up study.
Maintenance phase from Dec 2001 to Mar 2002.
Subdivided in three groups, one was administered the
sublingual allergoid, the others, injective I.T. and drugs.
Material & Methods
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy

57. One adverse event, after 300 IR/ml,
disappeared when adjusted at 30 IR.
No adverse events were noted after
administration of the allergoid SLIT.
Results
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy

61. To evaluate the efficacy, tolerability
and adherence to treatment of
allergoid sublingual immunotherapy
(I.T.), in comparison with injective
I.T. and drugs.
Objective
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years prospective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy

62. One hundred and ten allergic patients with rhino-
conjunctivitis and/or asthma.
Subdivided in three groups, one was administered the
sublingual allergoid, the others injective I.T. and drugs.
Prospective, observational, 36 months follow-up study.
Allergens: pollens and House Dust Mite.
Material & Methods
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy

63. Sublingual allergoid I.T. was
considered by patients and doctors to
be better than the other two therapies
(p<0.0001) as far as efficacy,
tolerability and patient’s compliance
concern.
Results
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy

64. Allergoid Sublingual I.T. was
positively appreciated by both
patients and physicians for its
simplicity of use, good efficacy and
the high degree of safety offered.
Conclusions
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al.
*ASL 5, Messina, °Pneumologia, Catania, Italy

66. SLIT with monomeric allergoid
• Effective in rhinoconjunctivitis and asthma
• Impeccable safety also in risk populations
• Perfectly tolerable in adults and children
• Outstanding compliance and adherence
• Internationally accepted by
– The Paul Ehrlich Institute

67. Thank you for the
attention
Paolo Falagiani
1947 - 2011